Abstract：
Background: LINC00518 acts as an oncogene in several cancers, but its function in head and neck squamous cell carcinoma (HNSCC) remains unclear. Materials & methods: The expression and methylation status of LINC00518 were analyzed by reviewing public databases. The ceRNA network and the relationship with tumor immunity of LINC00518 were analyzed using online tools and in vitro studies. Results: Upregulated LINC00518 was associated with poor clinicopathological characteristics of HNSCC. Silencing LINC00518 significantly inhibited the migration of HNSCC cells. LINC00518 might positively regulate HMGA2 via the ceRNA mechanism. Additionally, LINC00518 was negatively correlated with various immune cells and immunotherapy markers. Moreover, the upregulation of LINC00518 in HNSCC may be due to DNA hypomethylation. Conclusion: LINC00518 may be a potential biomarker and therapeutic target for HNSCC.
摘要：
背景：LINC00518在几种癌症中充当癌基因，但其在头颈部鳞状细胞癌（HNSCC）中的功能仍不清楚。材料和方法:通过查阅公共数据库分析LINC00518的表达和甲基化状态。使用在线工具和体外研究分析了LINC00518的ceRNA网络及其与肿瘤免疫的关系。结果：升高的LINC00518与HNSCC的临床病理特征较差有关。沉默LINC00518显著抑制HNSCC细胞的迁移。LINC00518可能通过ceRNA机制正向调节HMGA2。此外,LINC00518与各种免疫细胞和免疫治疗标志物呈负相关。此外，HNSCC中LINC00518的上调可能是由于DNA低甲基化所致。结论：LINC00518可能是HNSCC的潜在生物标志物和治疗靶点。
